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since the first cases of a1-antitrypsin deficiency (AATD)
were described. Since then a great deal of progress in many
aspects of this condition has been accomplished, including
better understanding of the pathophysiological mechanisms
leading to development of pulmonary emphysema related
to AATD, the creation of biochemical and molecular
diagnostic tools to screen for the condition, the recognition
of the broad spectrum of associated pulmonary and
extrapulmonary manifestations, a growing interest in the
world-wide epidemiology of the condition, and the devel-
opment of therapeutic strategies, with special emphasis on
AAT replacement therapy. One example of the increasing
awareness about AATD is the largest European national
registry for this condition, located in Sweden where the
condition was first recognized in 1963 (1), which stores
information on more than 900 AAT-deficient subjects
enrolled since then. Records on other large series of
patients are available in Denmark (700 subjects, starting
from 1976), Germany (more than 400 individuals, the
national registry having been set up in the 1980s), and The
Netherlands (more than 400 subjects, recruited during the
last 10 years). More recently established European regis-
tries, each with more than 150 subjects enrolled, exist in
Spain, Italy, and the United Kingdom. A large enrolment
programme sponsored by the National Institutes of Health
has led to the recruitment of 1129 AATD individuals in
North America (U.S.A. and Canada).
Replacement therapy with human plasma-derived AAT
was first licensed in the U.S.A. and is reserved for
individuals with severe AATD (AAT serum level 5
11 mM) (2), but is currently available in only a few countries,
including Germany, Spain and Italy.
Despite such tangible advances in the understanding and
management of AATD, many questions related to the
condition still wait for definitive answers. To address these
issues, a meeting was organized in spring 1996 in Geneva,
under the auspices of the World Health Organization. The
resulting document (3) recommended development of
standards of care for AATD subjects, improvement of
case-finding strategies in order to address the discrepancyCorrespondence should be addressed to: Maurizio Luisetti, MD,
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frequency data, only 10–50% of cases of AATD are
diagnosed in developed countries), and implementation of
randomized, placebo-controlled clinical trials to determine
the ecacy of intravenous AAT replacement therapy,
about which evidence is so far lacking.
Central to these recommendations was the suggestion
that an international registry of AATD be established. This
was considered a major winning strategy, since only the
collection of as large as possible a series of patients can
allow better understanding of the natural history of a rare
genetic disorder such as is AATD.
To comply with this recommendation, delegates from
some National Registries for AATD first met in Stockholm,
during the European Respiratory Society annual meeting in
September 1996. A general agreement to proceed in this
direction having been reached, a series of meetings, with the
invaluable support of Bayer, was arranged throughout 1997
and 1998 (Lisbon, March 1997; Berlin, September 1997;
Milan, February 1998). During these meetings, a temporary
coordinating committee was established, under the chair-
manship of Prof. Nikolaus Konietzko, and several issues
were extensively discussed. First of all, based on individual
experiences from countries already with running registries,
criteria to characterize AATD subjects in as standardized a
way as possible were identified in order to create a common
database for inclusion and follow-up of patients in the
International Registry. Among other topics, data confiden-
tiality issues, updating of independent research, plans for
future common studies, and sources for funding the
Registry, including application to European Union pro-
jects, were discussed.
Two years after the first, informal, exploratory meeting
in Stockholm, the recommendation from the WHO about
an International Registry became reality:
. In September 1998, during a meeting in Geneva, the
name, acronym and logo of the Registry were
approved (Alpha One International Registry,
A.I.R.). It currently includes 12 founding countries
(Australia, Canada, Denmark, Germany, Italy, New
Zealand, South Africa, Spain, Sweden, Switzerland,
The Netherlands and the United Kingdom), with the
prospect of broadening to other countries shortly. In
addition, the final draft of the questionnaire was
approved and its electronic version presented. Finally,# 2000 HARCOURT PUBLISHERS LTD
S2 M. LUISETTIa draft of the statutes of the A.I.R., as a Scientific
Society, was discussed.
. Eective from January 1999, the central database
located in Malmo¨ (Sweden) began to collect data on
AATD subjects electronically transferred by each
national registry.
. During a meeting in April 1999 in San Diego (CA,
U.S.A.), a new coordinating committee was elected,
and the statutes approved.
. The first open Scientific Meeting of the A.I.R. was
held in Cernobbio-Como (Italy) in June 1999; it was
attended by 120 delegates.
. In October 1999, the A.I.R. made its first public
appearance in a meeting of an International Scientific
Society, by organizing a crowded symposium during
the ERS Annual Meeting in Madrid.
Prof. Robert Stockley, the new chairman of the A.I.R.,
who has committed himself to taking the A.I.R. into the
21st century, hopes that over the next 5–10 years the society
will be able to identify as many AATD subjects as possible,design and implement appropriate clinical trials, advise
AATD individuals on how to improve their overall survival
and, perhaps, work towards new therapies. He closed the
1st Scientific Meeting of the A.I.R. stating that the registry
is now on its way to making a dierence. I cannot imagine a
better acknowledgement of the work done.
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